Abstract
BACKGROUND: CARD14-associated papulosquamous eruption (CAPE) is a spectrum of disease exhibited by patients with CARD14 mutations, which are rare and have a wide variety of clinical manifestations. Patients usually have limited response to traditional therapies. METHODS: We retrospectively analyzed a case series of 8 patients with CAPE in China. Whole-exome sequencing (WES) was performed in all patients to identify the mutation type. Three patients received the treatment of secukinumab with a 52-week follow-up period. They achieved 84.6%, 76.9%, and 68.8% improvement in PASI score, respectively. RESULTS: The study identified three new variants in CARD14 that had not been previously reported: c.392_397del, c.391_392delinsTT, and c.-280C>T. Three patients with different clinical manifestations showed good response to secukinumab. CONCLUSION: The mutation types in CARD14-associated papulosquamous eruption were various. IL-17A inhibitors, such as secukinumab, can be an alternative treatment option for pediatric patients with CAPE.